Biocon is lined up to copy 6 of the blockbuster drugs on this tracker, which earned $30.8B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Biocon's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entresto | Novartis | Generic | 2025 | Approved Aug 2024 | $7.7B |
| Stelara Yesintek |
Johnson & Johnson | Biosimilar | 2025 | FDA-approved biosimilar | $6.1B |
| Prolia Bosaya |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $4.4B |
| Xgeva Aukelso |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $2.1B |
| Farxiga | AstraZeneca | Generic | 2026 | Approved Apr 2026 | $8.4B |
| Cabometyx | Exelixis | Generic | 2031 | Settled Jul 2025 | $2.1B |
Company facts: Biocon. Each drug page lists sources for these entries. Brand sales show the size of the market, not Biocon's share of it.